CTOs on the Move

Syantra

www.syantra.com

 
With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.syantra.com
  • 105 - 32 Royal Vista Drive NW
    Calgary, AB CAN T3R 0H9
  • Phone: 877.331.0516

Executives

Name Title Contact Details

Similar Companies

Instil Bio

Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient`s own T cells harvested from the patient`s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells.

DiaKine Therapeutics

DiaKine Therapeutics is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DYNAMIS THERAPEUTICS

DYNAMIS THERAPEUTICS is a Jenkintown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Industrial Biotechnology Corporation

Industrial Biotechnology Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tyme

TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in using the body’s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostrate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. The SM-88, Tyme’s proprietary compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.